ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Brief Report
Revised

Mitochondrial dysfunction in an animal model of diabetic neuropathy is associated with a reduction of neurosteroid synthesis.

[version 2; peer review: 2 approved]
PUBLISHED 09 Mar 2018
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Background: Recent work in a model of diabetic neuropathy revealed that layer 2/3 cortical pyramidal neurones of the pain pathway exhibited reduced endogenous neurosteroid modulation of the GABAAR and exogenously applied neurosteroids had an exaggerated impact. It is postulated that this is related to reduced precursor synthesis, due to mitochondrial dysfunction in diabetic neuropathy. Benzodiazepines are also known to activate neurosteroidogenesis by binding to mitochondrial translocator protein (TSPO). This study explored the differential effect of diazepam on GABAAR modulation via neurosteroidogenesis in diabetic and wild type (WT) mice.
Methods: Whole-cell patch-clamp technique was used on slices of neural tissue. Electrophysiological recordings were obtained from layer 2/3 cortical pyramidal neurons of the pain pathway from mice with type-II diabetic neuropathy (ob/ob) and WT controls aged 60-80 days.
Results: There was a key difference in the response of the WT and ob/ob cortical neurons to simultaneous incubation with diazepam and flumazenil. In contrast, diazepam and the 5a-reductase inhibitor finasteride, individually or in combination, produced the same response in both strains.
Conclusions: The exaggerated effect of diazepam on GABAergic inhibitory tone in the ob/ob, despite the presence of the GABAAR benzodiazepine antagonist flumazenil is likely observed due to physiological upregulation of key neurosteroidogenic enzymes in response to the reduced pregnenolone synthesis by the mitochondria. By increasing pregnenolone via TSPO activation, it is possible to promote enhanced neurosteroidogenesis and increase GABAergic inhibitory tone via an alternate route. In diabetic neuropathy, mitochondrial dysfunction may play an important role. Enhancing the GABAergic neurosteroid tone could be of potential therapeutic benefit.

Keywords

Diabetes, neuropathic, pain, neurosteroid, benzodiazepine, ob/ob, mitochondria, TSPO, GABA

Revised Amendments from Version 1

Changes have been made in response to comments made by the reviewers. The title has been made more specific to the data presented. In the Abstract, "neuropathic pain" has been changed to "neuropathy" as the concept of pain is specific to humans, in contrast to nociception, which applies to mice and other species including humans. The Discussion has been edited to facilitate the reader’s understanding by putting the data in the context of recent work (Humble, 2016a). Similarly, Figure 1 and its legend have been edited in order to highlight action sites of diazepam, flumazenil and finasteride and therefore enhance readability. We have removed the mention of Dr Ladas from the Acknowledgements section, as this was accidentally added to the version 1.

See the author's detailed response to the review by Pascal Darbon
See the author's detailed response to the review by Slobodan M. Todorovic

Introduction

Diabetic neuropathy is a common cause of painful neuropathy, and treatment is often suboptimal because the underlying aetiology is poorly understood. Peripheral and central sensitisation are implicated in the development of neuropathic pain with neuroplasticity occurring at multiple levels of the pain pathway (Harvey & Dickenson, 2008). GABAergic neurones at all levels of the pain pathway have a vital role in the transmission of painful stimuli in the perception of pain itself (D’Mello & Dickenson, 2008). Endogenous and exogenous neurosteroids may act as potent positive allosteric modulators of GABAA receptors (GABAARs) and consequently exhibit analgesic, anxiolytic, anticonvulsant, and sedative properties (D'Hulst et al., 2009).

Within inhibitory synapses, the presynaptic fusion of a single vesicle releases the inhibitory neurotransmitter GABA to activate synaptic GABAARs. Under voltage-clamp conditions this causes a miniature inhibitory postsynaptic current (mIPSC). Drugs that enhance GABAAR function cause a prolongation of the mIPSC decay phase. Recent work in a model of type-II diabetic neuropathy (ob/ob) revealed that layer 2/3 cortical pyramidal neurones of the pain pathway exhibited reduced endogenous neurosteroid modulation of the GABAAR, and exogenously applied neurosteroids had an exaggerated impact (Humble, 2016a). The mechanism responsible appeared unrelated to GABAAR sensitivity, but instead was associated with a reduction of neurosteroid precursors, such as pregnenolone, which is metabolised sequentially to the active compound allopregnanolone (Figure 1) (Humble, 2013; Humble, 2016a). Pregnenolone is synthesised in the mitochondrion from its precursor cholesterol by the side chain cleavage enzyme P450 located in the inner mitochondrial membrane (Do Rego et al., 2009; Schumacher et al., 2012), and it is postulated that diabetic neuropathy may be associated with a reduction in mitochondrial activity. Cholesterol is translocated across the mitochondrial membrane by the 18 kDa translocator protein (TSPO) in a coordinated fashion with the steroidogenic acute regulatory (StAR) protein (Do Rego et al., 2009; Gatliff & Campanella, 2016; Rupprecht et al., 2010; Stocco et al., 2017; Figure 1).

9bc7056c-6c5f-4a12-b92e-e5f661059785_figure1.gif

Figure 1. Modulation of the GABAAR by endogenous neurosteroids.

Cholesterol is taken through the mitochondrial membrane by the translocator protein (TSPO) where it is converted to pregnenolone by the cytochrome P450 side chain cleavage enzyme. Pregnenolone is converted to progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD), which is in turn reduced to dihydroxyprogesterone by 5α-reductase (5α-R). Dihydroxyprogesterone is converted to allopregnanolone by 3α-hydroxysteroid dehydrogenase (3α-HSD). Postsynaptic GABAARs are activated by GABA that has been released from vesicles in the presynaptic nerve terminal. GABA induces a conformational change of the GABAAR, opening its central channel and thereby allowing the passage of chloride ions and the subsequent generation of miniature inhibitory postsynaptic currents (mIPSCs). The negative chloride ions induce hyperpolarisation of the neuronal membrane, which mediates neuronal inhibition. Neurosteroids, such as the active compound allopregnanolone, modulate GABAAR function and facilitate inhibition of the neuronal membrane. (Humble, 2013). The translocation of cholesterol into the mitochondria by TSPO is the first rate-limiting step and is enhanced by the presence of specific ligands such as diazepam. Thus diazepam may enhance GABAAR modulation by binding to the GABAAR directly and separately by increased neurosteroidogenesis. This modulation may be selectively inhibited at the GABAAR itself by the antagonist flumazenil and separately by the 5α-R inhibitor finasteride, which inhibits neurosteroidogenisis.

The present study explored the impact of the benzodiazepine diazepam, a positive allosteric modulator of the GABAAR (D’Hulst et al., 2009), on GABAAR modulation via neurosteroidogenesis in diabetic and wild type (WT) mice. Benzodiazepines are also known to activate neurosteroidogenesis by binding to TSPO (Rupprecht et al., 2010; Tokuda et al., 2010).

Methods

The methods are identical to those published by the same author previously (Humble, 2016a), with the exception of the drugs diazepam and flumazenil, which were not used in the previous study. Diazepam and flumazenil were purchased (Tocris, Bristol UK) and prepared as concentrated stock solutions in dimethyl sulfoxide before being added to the artificial extracellular solution as per the previous study (Humble, 2016a).

Results

Prolonged exposure (2 hrs) of mature cortical neurones to diazepam (1μM) in the presence of flumazenil had an exaggerated effect on the cortical GABAAR-mediated mIPSCs of ob/ob mice in comparison to WT mice

Whole-cell voltage-clamp recordings were made in L2/3 cortical neurones of WT and ob/ob mice after at least two hours of incubation with diazepam, flumazenil and finasteride. Diazepam alone had the same effect on both strains of mice. In the WT mice, flumazenil inhibited the effect of diazepam (τW: control = 4.0 ± 0.1 ms, n = 35; finasteride 50 μM = 4.2 ± 0.1 ms, n = 7; diazepam 1 μM = 5.9 ± 0.2 ms, n = 6; flumazenil 10 μM & diazepam 1 μM = 4.0 ± 0.2 ms, n = 7; flumazenil 10 μM, finasteride 50 μM & diazepam 1 μM = 4.0 ± 0.3 ms, n = 6; One-way ANOVA, P <0.05; post hoc Newman Keul’s test revealed a difference only for diazepam 1 μM, P <0.05; Figure 2). By contrast, in the ob/ob mice, flumazenil only partially inhibited the effect of diazepam, and the persisting effect of diazepam in the presence of flumazenil in the ob/ob mice could be prevented by the presence of the 5α-reductase enzyme inhibitor finasteride (τW: ob/ob control = 3.5 ± 0.1 ms, n = 25; finasteride 50 μM = 3.7 ± 0.2 ms, n = 6; diazepam 1 μM = 5.7 ± 0.3 ms, n = 6; flumazenil 10 μM & diazepam 1 μM = 4.9 ± 0.3 ms, n = 6; flumazenil 10 μM, finasteride 50 μM & diazepam 1 μM = 3.7 ± 0.1 ms, n = 5; One-way ANOVA, P <0.05; post hoc Newman Keul’s test revealed significant intergroup differences for the flumazenil groups, P <0.05; Figure 2).

9bc7056c-6c5f-4a12-b92e-e5f661059785_figure2.gif

Figure 2. Prolonged exposure (2 hrs) of mature cortical neurones to diazepam (1 μM) in the presence of flumazenil had an exaggerated effect on the cortical GABAAR-mediated mIPSCs of ob/ob mice in comparison to WT mice.

(A) Superimposed exemplar averaged GABAAR-mediated miniature inhibitory postsynaptic currents (mIPSCs) acquired from a representative WT cortical neurone and from equivalent neurones after ~2 hours pre-incubation of the brain slice with diazepam (1 μM), flumazenil (10 μM) and finasteride (50 μM). (B) Superimposed exemplar averaged GABAAR-mediated mIPSCs acquired from a representative ob/ob cortical neurone and from equivalent neurones after ~2 hours pre-incubation of the brain slice with diazepam (1μM), flumazenil (10 μM) and finasteride (50 μM). (C) Histogram illustrating that flumazenil is able to prevent the effect of diazepam to prolong the duration of the GABAAR-mediated mIPSC in WT cortical neurones, but only has a partial efficacy in ob/ob cortical neurones (τw in ms; one-way ANOVA, P >0.05; Post hoc Newman Keul’s test). The persisting effect of diazepam in the presence of flumazenil in the ob/ob mice could be prevented by the presence of the 5α-reductase enzyme inhibitor finasteride (τw in ms; one-way ANOVA, P >0.05; Post hoc Newman Keul’s test). Ctrl = control; Finast = finasteride; Diaz = diazepam; Flumaz = flumazenil.

Discussion

Layer 2/3 cortical neurones from mature type-II diabetic ob/ob are known to have a reduced endogenous pregnane-derived neurosteroid tone in comparison to strain matched WT controls (Humble, 2016a). The present data indicate that by promoting the uptake of pregnenolone’s precursor cholesterol by the mitochondria, via TSPO, diazepam may rescue the reduced neurosteroid tone. The restored neurosteroid tone could re-establish GABAAR-mediated neuro-inhibitory tone in cases of neuropathic hypersensitivity. With specific reference to these data, the key result is the difference in response of the WT and ob/ob to simultaneous incubation with diazepam and flumazenil. In contrast, diazepam and the 5α-reductase inhibitor finasteride individually or in combination produced the same response in both WT and ob/ob. This may be interpreted as follows: in the WT, the primary effect of diazepam incubation is direct allosteric modulation of the GABAAR, with negligible contribution from neurosteroidogenesis via mitochondrial TSPO activation. In comparison, diazepam has an exaggerated effect on GABAergic inhibitory tone in the ob/ob, despite the presence of the GABAAR benzodiazepine antagonist flumazenil. This effect is likely observed due to physiological upregulation of the key rate-limiting enzymes involved in neurosteroidogenesis in response to the reduced pregnenolone synthesis by the mitochondria (Figure 1; Humble, 2016a). Thus by increasing the availability of the neurosteroid precursor pregnenolone via TSPO activation, it is possible to promote enhanced neurosteroidogenesis and thereby increase GABAergic inhibitory tone via an alternate route. Benzodiazepines modulate the GABAAR by binding to the α-γ subunit interface (D'Hulst et al., 2009), while neurosteroids bind the GABAAR from a cavity within the α-subunit domain and modulate it directly via the α-β subunit interface (Hosie et al., 2006). There have already been a number of other studies of ligands for the mitochondrial TSPO, as this is a promising target (Gatliff & Campanella, 2016; Giatti et al., 2009; Papadopoulos & Lecanu, 2009; Rupprecht et al., 2010; Zhang et al., 2016). Considering the findings in this paper alongside previous work (Humble, 2016a) it appears that mitochondrial dysfunction may play an important role in the development of type 2 diabetic neuropathy. In this context, it follows that enhancing the GABAergic neurosteroid tone directly or indirectly could be of potential therapeutic benefit for diabetic neuropathic pain and hypersensitivity.

Data availability

Open Science Framework: Dataset of ‘Neurosteroids are reduced in diabetic neuropathy and may be associated with the development of neuropathic pain’, doi: 10.17605/osf.io/bk3tw (Humble, 2016b). Raw data for the present study can be found in Diazepam.zip.

Please refer to (Humble, 2016a) for details of standard software used for data analysis.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 18 Apr 2017
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Humble SR. Mitochondrial dysfunction in an animal model of diabetic neuropathy is associated with a reduction of neurosteroid synthesis. [version 2; peer review: 2 approved]. F1000Research 2018, 6:506 (https://doi.org/10.12688/f1000research.11056.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 2
VERSION 2
PUBLISHED 09 Mar 2018
Revised
Views
8
Cite
Reviewer Report 20 Mar 2018
Slobodan M. Todorovic, Department of Anesthesiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA 
Approved
VIEWS 8
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Todorovic SM. Reviewer Report For: Mitochondrial dysfunction in an animal model of diabetic neuropathy is associated with a reduction of neurosteroid synthesis. [version 2; peer review: 2 approved]. F1000Research 2018, 6:506 (https://doi.org/10.5256/f1000research.15396.r31739)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 18 Apr 2017
Views
14
Cite
Reviewer Report 06 Jun 2017
Pascal Darbon, Institut des Neurosciences Cellulaires et Intégratives (INCI), UPR 3212 CNRS, Centre National de la Recherche Scientifique and University of Strasbourg, Strasbourg Cedex, France 
Approved
VIEWS 14
The present article is a follow-up of Humble’s previous paper in F1000Research (Humble SR. Neurosteroids are reduced in diabetic neuropathy and may be associated with the development of neuropathic pain [version 1; referees: 1 approved, 2 approved with reservations]. F1000Research ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Darbon P. Reviewer Report For: Mitochondrial dysfunction in an animal model of diabetic neuropathy is associated with a reduction of neurosteroid synthesis. [version 2; peer review: 2 approved]. F1000Research 2018, 6:506 (https://doi.org/10.5256/f1000research.11924.r23003)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 15 Jun 2017
    Stephen Humble, Department of Anaesthetics and Pain Management, Charing Cross Hospital, Imperial College NHS Healthcare Trust London, London, W6 8RF, UK
    15 Jun 2017
    Author Response
    Dear Prof Darbon,

    Thank you for your comments and for taking the time to review the paper. I agree that the illustration and description could be improved and I will do ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 15 Jun 2017
    Stephen Humble, Department of Anaesthetics and Pain Management, Charing Cross Hospital, Imperial College NHS Healthcare Trust London, London, W6 8RF, UK
    15 Jun 2017
    Author Response
    Dear Prof Darbon,

    Thank you for your comments and for taking the time to review the paper. I agree that the illustration and description could be improved and I will do ... Continue reading
Views
19
Cite
Reviewer Report 30 May 2017
Slobodan M. Todorovic, Department of Anesthesiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA 
Approved with Reservations
VIEWS 19
My major concern with this study is that title and discussion are not relevant to the data presented. There is no justification to link this study to neuropathic pain or painful diabetic neuropathy. Perhaps more appropriate title would be:
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Todorovic SM. Reviewer Report For: Mitochondrial dysfunction in an animal model of diabetic neuropathy is associated with a reduction of neurosteroid synthesis. [version 2; peer review: 2 approved]. F1000Research 2018, 6:506 (https://doi.org/10.5256/f1000research.11924.r22166)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 09 Mar 2018
    Stephen Humble, Department of Anaesthetics and Pain Management, Charing Cross Hospital, Imperial College NHS Healthcare Trust London, London, W6 8RF, UK
    09 Mar 2018
    Author Response
    Dear Prof Todorovic,
     
    Thank you for taking the time to review the paper. I agree that the title should be changed. I have reworded it as follows in relation to your ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 09 Mar 2018
    Stephen Humble, Department of Anaesthetics and Pain Management, Charing Cross Hospital, Imperial College NHS Healthcare Trust London, London, W6 8RF, UK
    09 Mar 2018
    Author Response
    Dear Prof Todorovic,
     
    Thank you for taking the time to review the paper. I agree that the title should be changed. I have reworded it as follows in relation to your ... Continue reading

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 18 Apr 2017
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.